RxDoctor Payments Data

John Beckner, MD

Psychiatry · Eton, GANPI 1538212519

Payments from drug & device makers

$5,527in general payments, 2019–2025

Across 301 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$754
  • AbbVie$726
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$712
  • Neurocrine Biosciences, Inc.$608
  • Otsuka America Pharmaceutical, Inc.$552
  • Johnson & Johnson$408
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,42998%
  • Education$982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,527 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$55,474
Medicare patients
149
Services billed
503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl88$124,926
Invega SustennaPaliperidone Palmitate13$52,232
AuvelityDextromethorphan Hbr/Bupropion45$51,322
Abilify MaintenaAripiprazole15$39,163
LybalviOlanzapine/Samidorphan Malate23$36,138
RexultiBrexpiprazole23$34,127
CaplytaLumateperone Tosylate18$28,885
BelsomraSuvorexant45$21,234
Lurasidone Hcl57$17,387
Aripiprazole157$12,633
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine176$5,325
Chlorpromazine Hcl11$4,896
Paliperidone ErPaliperidone16$4,515
Duloxetine Hcl316$3,970
Hydroxyzine Hcl185$3,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$726$124,92688 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$552$73,29038 claims
Johnson & JohnsonInvega Sustenna$408$52,23213 claims
Axsome Therapeutics, Inc.Auvelity$62$51,32245 claims
Alkermes, Inc.Lybalvi$224$36,13823 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$712$28,88518 claims
MerckBelsomra$66$21,23445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Eton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →